ValiRx plc (AIM:VAL)
London · Delayed Price · Currency is GBP · Price in GBX 0.1300
+0.0050 (4.00%)
Sep 25, 2026, 3:40 PM GMT
ValiRx Revenue
ValiRx had revenue of 1.30K GBP in the half year ending June 30, 2026. This brings the company's revenue in the last twelve months to 32.67K, down -34.36% year-over-year. In the year 2025, ValiRx had annual revenue of 31.37K, down -36.97%.
Revenue (ttm)
32.67K
Revenue Growth
-34.36%
P/S Ratio
50.51
Revenue / Employee
2.97K
Employees
11
Market Cap
1.65M
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 31.37K | -18.40K | -36.97% |
| Dec 31, 2024 | 49.78K | 40.18K | 418.49% |
| Dec 31, 2023 | 9.60K | - | - |
| Dec 31, 2022 | - | - | - |
| Dec 31, 2021 | - | - | - |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Futura Medical | 2.32M |
| Aptamer Group | 1.38M |
| OptiBiotix Health | 1.29M |
| Physiomics | 1.01M |
| CRISM Therapeutics | 352.00K |
| BSF Enterprise | 51.07K |
| Solvonis Therapeutics | 31.87K |
| Thalia Therapeutics | 7.26K |
ValiRx News
- 2 months ago - AIM Market Roundup: Galileo Resources, Valirx, Beowulf Mining - The Armchair Trader
- 11 months ago - AIM Market Roundup: Haydale Graphene, Marechale Capital, Getech - The Armchair Trader
- 1 year ago - Small Cap Stocks: Catenai, Genip, ValiRx - The Armchair Trader
- 1 year ago - Small Cap Stocks: Guardian Metal, MediaZest, Enwell - The Armchair Trader
- 1 year ago - Small Cap Stocks: Valirx, EnergyPathways, Merit Group - The Armchair Trader